Crescita Therapeutics Inc.
Crescita Therapeutics Inc. (CTX.TO) Revenue
Annual & quarterly revenue history · segment & region breakdown
CTX.TO · revenue · updated Jun 8, 2026
Core revenue metrics
Trailing 12 monthsCrescita Therapeutics Inc. trailing twelve-month (TTM) revenue is $0.02B, an increase of 7.85% year-over-year from $0.02B in FY2025.
Revenue trend
2025 – 2014 · AnnualRevenue history
| Fiscal year end | Revenue | Change | Growth |
|---|---|---|---|
| 2025-12-31 | $0.02B | +$0.00B | +7.85% |
| 2024-12-31 | $0.02B | +$0.00B | +11.75% |
| 2023-12-31 | $0.02B | -$0.01B | -25.52% |
| 2022-12-31 | $0.02B | +$0.01B | +40.29% |
| 2021-12-31 | $0.02B | +$0.00B | +7.22% |
| 2020-12-31 | $0.02B | -$0.01B | -29.98% |
| 2019-12-31 | $0.02B | +$0.01B | +34.33% |
| 2018-12-31 | $0.02B | +$0.00B | +38.41% |
| 2017-12-31 | $0.01B | +$0.01B | +242.87% |
| 2016-12-31 | $0.00B | +$0.00B | +308.87% |
About Revenue & Reporting
Revenue (also called sales, net sales, or turnover) is the total income Crescita Therapeutics Inc. receives from its business operations before deducting any costs or expenses. It is the top line of the income statement. Unlike net income or earnings, revenue does not account for operating costs, taxes, interest, or depreciation.
Crescita Therapeutics Inc. reports revenue on a fiscal year ending Dec 31 basis under US GAAP, denominated in CAD.
Data sourced from Crescita Therapeutics Inc.'s 10-K and 10-Q SEC filings via Financial Modeling Prep.
Frequently asked questions
CTX.TO revenue · 4 questionsCTX.TO's trailing twelve-month (TTM) revenue is $0.02B. That is an increase of 7.85% year-over-year from $0.02B in FY2025.
▸ Source: FMP · Crescita Therapeutics Inc. SEC filings · GAAP · Crescita Therapeutics Inc. SEC 10-K & 10-Q filings · US GAAP · Updated: Jun 8, 2026